MedPath

Elixir Medical's DynamX BTK System Receives FDA Breakthrough Device Designation for Chronic Limb-Threatening Ischemia

• Elixir Medical's DynamX BTK System receives FDA Breakthrough Device Designation for treating below-the-knee arterial disease in chronic limb-threatening ischemia (CLTI) patients. • The DynamX Bioadaptor platform aims to restore vessel function by providing dynamic support during healing and maintaining an open lumen in affected vessels. • The breakthrough designation expedites the review process, acknowledging the technology's potential to address unmet needs in treating severe peripheral arterial disease. • Clinical data has demonstrated the Bioadaptor's ability to achieve high acute lumen gain and restore vessel motion, potentially improving outcomes in BTK revascularization.

Elixir Medical has announced that its DynamX BTK System has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This designation is for the treatment of narrowed or blocked vessels below-the-knee (BTK) in patients suffering from chronic limb-threatening ischemia (CLTI), the most severe form of peripheral arterial disease (PAD). The DynamX BTK System expands the application of Elixir's bioadaptor platform beyond coronary artery disease.
The DynamX Bioadaptor is designed to support the vessel during the healing phase, after which it unlocks to restore vessel function and maintain an open lumen. This mechanism aims to address the challenges of existing BTK therapies, such as maintaining long-term lumen gain.

The Burden of Peripheral Arterial Disease

PAD affects over 200 million people globally. CLTI, the advanced stage of PAD, carries a high risk of mortality, with one-year mortality estimates exceeding 20% in observational studies. Without revascularization, a significant number of CLTI patients require major amputation.

How DynamX Bioadaptor Works

The DynamX Bioadaptor has demonstrated high acute lumen gain in coronary vessels and maintained this gain over time. It also restores vessel motion and function, including positive adaptive remodeling, vessel pulsatility, improved vessel dynamic compliance, and increased blood flow volume.
"The Bioadaptor platform was developed to transform treatment of coronary and peripheral artery disease," said Motasim Sirhan, CEO at Elixir Medical. "We appreciate the FDA recognition of our innovation for treating the CLTI population with BTK disease and its potential impact on the patients suffering from vascular disease."

FDA Breakthrough Device Designation

The FDA Breakthrough Device Designation is granted to novel technologies that address unmet medical needs, accelerating their review process. Devices receiving this designation must meet rigorous standards for safety and effectiveness before being authorized for marketing.

About DynamX Bioadaptor Technology

The DynamX Bioadaptor is designed to unlock, uncage, and restore normal vessel motion and function after percutaneous coronary intervention (PCI) or BTK intervention. It maintains dynamic support of the diseased vessel after uncaging, aiming to set a new standard of care for vascular intervention.
The DynamX BTK System is currently not available for sale in the U.S.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Xeltis' aXess Receives FDA Breakthrough Device Designation and Enrolls First Patient in Pivotal Trial

Xeltis' aXess, a synthetic vascular access device, has been granted Breakthrough Device designation by the FDA, expediting its path to market.
The pivotal trial, a prospective, single-arm, multi-center study, is evaluating the safety and performance of aXess in adults with end-stage renal disease needing dialysis.

Xeltis' aXess Receives FDA Breakthrough Device Designation and Enrolls First Patient in Pivotal Trial

Xeltis' aXess, a synthetic vascular access device, has been granted Breakthrough Device designation by the FDA, expediting its path to market through prioritized review and enhanced interaction with FDA experts.
The company has enrolled and treated the first patient in its US pivotal trial, a prospective, single-arm, multi-center study evaluating the safety and performance of aXess in adults with end-stage renal disease needing dialysis.

Xeltis' aXess Receives FDA Breakthrough Device Designation and Enrolls First Patient in US Pivotal Trial

Xeltis' aXess vascular access conduit receives FDA Breakthrough Device Designation, expediting its development and review for hemodialysis patients.
The designation acknowledges aXess' potential to offer a more effective vascular access option, reducing reinterventions and complications for dialysis patients.

QuantalX's Delphi Stimulator Receives FDA Clearance for Advancing Brain Health Diagnosis

QuantalX has received FDA clearance for its Delphi stimulator, a novel device designed for direct brain health diagnosis at the point of care.
The Delphi-MD platform enables early detection of brain abnormalities across conditions like stroke, dementia, Parkinson's Disease, and traumatic brain injury.

R3 Vascular's MAGNITUDE Scaffold Receives FDA IDE Approval for BTK-PAD Trial

R3 Vascular's MAGNITUDE, a next-generation drug-eluting bioresorbable scaffold, has received FDA IDE approval for its ELITE-BTK pivotal trial.
The ELITE-BTK trial will evaluate MAGNITUDE's impact on outcomes for patients with Chronic Limb-Threatening Ischemia due to below-the-knee PAD.

R3 Vascular's Magnitude Scaffold Receives FDA IDE for BTK-PAD Trial

R3 Vascular secured FDA IDE approval for its Magnitude drug-eluting bioresorbable scaffold, designed for treating below-the-knee peripheral arterial disease.
The ELITE-BTK pivotal trial, set to begin in Q1 2025, will evaluate the next-generation scaffold at up to 60 global sites with 264 subjects.

R3 Vascular's MAGNITUDE Scaffold Receives FDA Approval for BTK PAD Trial

The FDA has approved R3 Vascular to begin the ELITE-BTK trial for its MAGNITUDE drug-eluting bioresorbable scaffold, targeting below-the-knee peripheral arterial disease.
The MAGNITUDE scaffold, made from ultra-high molecular weight polylactic acid polymer, is designed to gradually absorb into the tissue while providing structural support.

FDA Approves Reformulated Denileukin Diftitox (Lymphir) for Relapsed/Refractory Cutaneous T-Cell Lymphoma

The FDA has approved denileukin diftitox-cxdl (Lymphir) for relapsed/refractory cutaneous T-cell lymphoma (CTCL) after one or more prior systemic therapies.
Denileukin diftitox is a recombinant fusion protein targeting the CD25 component on malignant T cells, offering a targeted therapeutic approach.

Elixir Medical's DynamX Bioadaptor Shows Strong Results in Complex Coronary Lesions

Elixir Medical's DynamX bioadaptor demonstrated an 83% reduction in target lesion failure (TLF) compared to Medtronic's Resolute Onyx in ACS patients.
The INFINITY-SWEDEHEART trial highlighted the bioadaptor's benefits in complex lesions, including those in the LAD artery and small vessels.

Amphix Bio's Bone Regeneration Product Receives FDA Breakthrough Device Designation

Amphix Bio's drug-device combination for bone regeneration has received FDA Breakthrough Device designation, expediting its development and review.
The designation targets the treatment of degenerative disc disease via transforaminal lumbar interbody fusion (TLIF) procedures.

Reference News

[1]
Elixir Medical Receives FDA Breakthrough Device Designation for the DynamX BTK System for Use in the Treatment of Chronic Limb-Threatening Ischemia Resulting From Below-The-Knee Arterial Disease
finance.yahoo.com · Mar 21, 2024

Elixir Medical's DynamX® BTK System, a novel bioadaptor platform for treating chronic limb-threatening ischemia (CLTI) i...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy